IRWD — Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc (IRWD) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Thomas A. McCourt, based in 100 Summer Street, Boston, MA, United States, 02110, with about 100 employees. Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Latest reported IRWD revenue for 2025-09-30 was $122.1M. Net income was $40.1M. Revenue was up 43.2% from 2025-06-30 to 2025-09-30. IRWD currently screens at market cap $579.4M and trailing P/E 5.7.

Use this IRWD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IRWD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IRWD SEC filings page. Lician reads the product cache first so this HTML stays unique to Ironwood Pharmaceuticals Inc even when a live quote feed is slow.